These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3139859)

  • 21. The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration.
    Gordon JD; Riggs KW; Rurak DW; Kwan E; Hall C; Abbott FS
    Drug Metab Dispos; 1995 Dec; 23(12):1383-9. PubMed ID: 8689948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
    Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats.
    Katayama H; Mizukami K; Yasuda M; Hatae T
    J Pharm Sci; 2016 Oct; 105(10):3199-3204. PubMed ID: 27499337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition and protein binding of valproic acid in the developing rat.
    Haberer LJ; Pollack GM
    Drug Metab Dispos; 1994; 22(1):113-9. PubMed ID: 8149869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits.
    Nakashima M; Takeuchi N; Hamada M; Matsuyama K; Ichikawa M; Goto S
    Biol Pharm Bull; 1994 Dec; 17(12):1630-4. PubMed ID: 7735208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronopharmacokinetics of valproic acid following constant-rate administration in mice.
    Ohdo S; Nakano S; Ogawa N
    Chronobiol Int; 1991 Feb; 8(1):35-43. PubMed ID: 1814601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of drug disposition kinetics in skin and plasma following topical administration.
    Guy RH; Hadgraft J
    J Pharm Sci; 1984 Jul; 73(7):883-7. PubMed ID: 6470948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
    Mei S; Feng W; Zhu L; Li X; Yu Y; Yang W; Gao B; Wu X; Fang F; Zhao Z
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1029-1036. PubMed ID: 29666902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.
    Yamamura N; Imura K; Naganuma H; Nishimura K
    Drug Metab Dispos; 1999 Jun; 27(6):724-30. PubMed ID: 10348803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
    Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
    Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of a dopamine receptor agonist and atropine sulfate on absorption of valproic acid in rats.
    Kameya H; Hokama N; Hobara N; Ohshiro S; Uno T
    Biomed Res; 2009 Apr; 30(2):101-6. PubMed ID: 19420733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of the two-compartment open model with Michaelis-Menten elimination kinetics to valproic acid in the bile-exteriorized rat.
    Lawyer CH; Gerber N; Lynn RK; Dickinson RG
    Res Commun Chem Pathol Pharmacol; 1980 Mar; 27(3):469-84. PubMed ID: 6770426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous absorption of acemetacin from a membrane controlled transdermal system and prediction of the disposition of the drug in rats.
    Ito Y; Ogiso T; Iwaki M; Tanino T; Terao M
    Biol Pharm Bull; 1993 Jun; 16(6):583-8. PubMed ID: 8364511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentration-dependent disposition of glucuronide metabolite of valproate.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic analysis of ester prodrugs of valproic acid.
    Hadad S; Vree TB; van der Kleijn E; Bialer M
    J Pharm Sci; 1992 Oct; 81(10):1047-50. PubMed ID: 1432619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of valproic acid in patients with bipolar disorder.
    Vasudev K; Das S; Goswami U; Tayal G
    J Psychopharmacol; 2001 Sep; 15(3):187-90. PubMed ID: 11565626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired biliary elimination of beta-glucuronidase-resistant "glucuronides" of valproic acid after intravenous administration in the rat. Evidence for oxidative metabolism of the resistant isomers.
    Dickinson RG; Kluck RM; Wood BT; Eadie MJ; Hooper WD
    Drug Metab Dispos; 1986; 14(2):255-62. PubMed ID: 2870903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.